Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

被引：0
|
作者：
Pia Wegman
Sauli Elingarami
John Carstensen
Olle Stål
Bo Nordenskjöld
Sten Wingren
机构：
[1] Linköping University,Department of Biomedicine and Surgery, Division of Cell Biology, Faculty of Health Sciences
[2] Linköping University,Department of Health and Society, Faculty of Arts and Sciences
[3] Linköping University,Department of Biomedicine and Surgery, Division of Oncology, Faculty of Health Sciences
来源：
Breast Cancer Research | / 9卷
关键词：
Breast Cancer; Tamoxifen; Postmenopausal Patient; Tamoxifen Therapy; Homozygous Carrier;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population
    Mutawi, Thuraya M.
    Zedan, Mohamed M.
    Yahya, Raida S.
    Zakria, Mahmoud M.
    El-Sawi, Mamdouh R.
    Gaedigk, Andrea
    PHARMACOGENOMICS, 2021, 22 (06) : 323 - 334
  • [22] CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
    Rae, James M.
    Drury, Suzy
    Hayes, Daniel F.
    Stearns, Vered
    Thibert, Jacklyn N.
    Haynes, Ben P.
    Salter, Janine
    Sestak, Ivana
    Cuzick, Jack
    Dowsett, Mitch
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06): : 452 - 460
  • [23] Re: CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer Response
    Berry, Donald A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (02):
  • [24] CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy
    Thompson, A. M.
    Bray, S.
    Johnson, A. M.
    Quinlan, P.
    Nikloff, D. M.
    Evans, D. G.
    Clarke, R.
    Lawrence, H. J.
    Howell, A.
    Latif, A.
    Ferraldeschl, R.
    Hillman, G.
    Fontecha, M.
    Newman, W. G.
    BREAST CANCER RESEARCH, 2010, 12 : S15 - S15
  • [25] CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
    Berry, Donald
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (17): : 1267 - 1269
  • [26] CYP2D6 and tamoxifen: DNA matters in breast cancer
    Janelle M. Hoskins
    Lisa A. Carey
    Howard L. McLeod
    Nature Reviews Cancer, 2009, 9 : 576 - 586
  • [27] CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy
    AM Thompson
    S Bray
    AM Johnson
    P Quinlan
    DM Nikloff
    DG Evans
    R Clarke
    HJ Lawrence
    A Howell
    A Latif
    R Ferraldeschl
    G Hillman
    M Fontecha
    WG Newman
    Breast Cancer Research, 12
  • [28] CYP2D6 and adjuvant tamoxifen: Impact on outcome in pre- but not postmenopausal breast cancer patients
    Margolin, S.
    Lindh, J.
    Thoren, L.
    Xie, H.
    Koukel, L.
    Dahl, M-L
    Eliasson, E.
    CANCER RESEARCH, 2012, 72
  • [29] CYP2D6 and tamoxifen: DNA matters in breast cancer
    Hoskins, Janelle M.
    Carey, Lisa A.
    Mcleod, Howard L.
    NATURE REVIEWS CANCER, 2009, 9 (08) : 576 - 586
  • [30] Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen
    Carmen W. H. Chan
    Bernard M. H. Law
    Winnie K. W. So
    Ka Ming Chow
    Mary M. Y. Waye
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1395 - 1404
12345